ADVERTISEMENT
Melinta Therapeutics appoints Sunitha Lakshminarayanan as CTO
Sunitha Lakshminarayanan held several leadership roles throughout her career, with a focus on ensuring product quality and regulatory compliance.
.jpeg)
Sunitha Lakshminarayanan. / Image – LinkedIn
New Jersey-based biopharmaceutical company, Melinta Therapeutics, has appointed Indian-American executive Sunitha Lakshminarayanan as chief technology officer (CTO), effective immediately.
With over 20 years of experience in chemistry, manufacturing, and controls (CMC), Lakshminarayanan brings a vast array of expertise in developing and commercializing a wide range of products, including small molecules, biologics, vaccines, and cell and gene therapies.
As the new CTO, Lakshminarayanan will oversee Melinta's global quality and supply chain operations, ensuring timely delivery of clinical and commercial products while working with president and CEO, Christine Ann Miller, to drive operational efficiency and strategic planning for the company's technical operations.
“We are thrilled to welcome Sunitha as chief technology officer at Melinta,” Miller said. “Her track record of driving operational excellence, engaging in strategic negotiations with suppliers and CMOs, strategizing in response to market dynamics, and overseeing product and supply planning make Sunitha the perfect leader to take on the challenges of this role.”
Commenting on her new role Lakshminarayanan said, “I am truly honored by the opportunity to join this amazing group of dedicated and passionate professionals at Melinta. Ensuring timely and quality compliant drug supply to patients is exciting and deeply fulfilling. I know that together we will continue to ensure that all people who need these vital therapies receive them.”
Before joining Melinta, Lakshminarayanan served as senior vice president of Technical Operations at Actinium Pharmaceuticals, where she oversaw operations across CDMO, regulatory, quality, and supply chain functions. She previously worked at Bristol-Myers Squibb, managing global licensure for cell therapy products, and held leadership positions at Kashiv BioSciences, Progenics Pharmaceuticals, and Laureate Pharma.
Lakshminarayanan holds an M.B.A. from the Kellogg School of Management, a Master’s in chemical engineering from Penn State University, and a bachelor’s in chemical engineering from Coimbatore Institute of Technology in India.
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
.jpg)
.png)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login